Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Ultrasonography | 11 | 2021 | 4409 | 1.15 | Why? |
| Immunoglobulin Light-chain Amyloidosis | 6 | 2018 | 94 | 0.98 | Why? |
| Foreign Bodies | 1 | 2021 | 171 | 0.69 | Why? |
| Wounds, Gunshot | 1 | 2021 | 248 | 0.67 | Why? |
| Vena Cava, Inferior | 1 | 2018 | 103 | 0.67 | Why? |
| Eosinophils | 1 | 2020 | 848 | 0.53 | Why? |
| Organ Dysfunction Scores | 1 | 2018 | 1475 | 0.45 | Why? |
| Lung Injury | 1 | 2020 | 919 | 0.43 | Why? |
| Leukocyte Count | 1 | 2020 | 3178 | 0.42 | Why? |
| Immunoglobulin Light Chains | 3 | 2017 | 62 | 0.37 | Why? |
| Point-of-Care Systems | 3 | 2020 | 2955 | 0.35 | Why? |
| Emergency Service, Hospital | 4 | 2020 | 14232 | 0.34 | Why? |
| Point-of-Care Testing | 1 | 2020 | 2782 | 0.33 | Why? |
| Sympathectomy, Chemical | 1 | 2005 | 1 | 0.32 | Why? |
| Doxazosin | 1 | 2005 | 27 | 0.32 | Why? |
| Adrenergic alpha-Antagonists | 1 | 2005 | 9 | 0.32 | Why? |
| Matrix Metalloproteinase 2 | 3 | 2019 | 85 | 0.31 | Why? |
| Cardiomegaly | 1 | 2005 | 96 | 0.29 | Why? |
| Education, Medical, Undergraduate | 1 | 2018 | 1392 | 0.28 | Why? |
| Italy | 15 | 2021 | 38444 | 0.26 | Why? |
| Dyspnea | 1 | 2017 | 3847 | 0.26 | Why? |
| Emergency Medical Services | 1 | 2020 | 3557 | 0.26 | Why? |
| Internal Medicine | 2 | 2021 | 557 | 0.25 | Why? |
| Lung | 11 | 2021 | 31049 | 0.25 | Why? |
| Clinical Competence | 1 | 2018 | 3263 | 0.25 | Why? |
| Bortezomib | 3 | 2017 | 125 | 0.24 | Why? |
| Matrix Metalloproteinase 9 | 2 | 2019 | 211 | 0.22 | Why? |
| Sepsis | 1 | 2018 | 3517 | 0.22 | Why? |
| Fatty Acid Desaturases | 1 | 2019 | 11 | 0.20 | Why? |
| Gelatinases | 1 | 2019 | 7 | 0.20 | Why? |
| Non-alcoholic Fatty Liver Disease | 2 | 2019 | 907 | 0.19 | Why? |
| Oxidative Stress | 3 | 2019 | 2050 | 0.19 | Why? |
| Wireless Technology | 1 | 2020 | 180 | 0.19 | Why? |
| Students, Medical | 1 | 2018 | 4032 | 0.18 | Why? |
| Amyloidogenic Proteins | 1 | 2017 | 30 | 0.18 | Why? |
| Bendamustine Hydrochloride | 1 | 2017 | 41 | 0.17 | Why? |
| Thalidomide | 2 | 2017 | 247 | 0.17 | Why? |
| Antineoplastic Agents, Alkylating | 1 | 2017 | 71 | 0.17 | Why? |
| Renal Insufficiency, Chronic | 3 | 2021 | 2654 | 0.17 | Why? |
| Echocardiography, Doppler | 2 | 2018 | 269 | 0.17 | Why? |
| Learning Curve | 1 | 2018 | 157 | 0.16 | Why? |
| Natriuretic Peptides | 1 | 2017 | 66 | 0.16 | Why? |
| Aged, 80 and over | 15 | 2022 | 88759 | 0.16 | Why? |
| Predictive Value of Tests | 3 | 2020 | 9537 | 0.16 | Why? |
| Pneumonia, Viral | 14 | 2020 | 243684 | 0.16 | Why? |
| Coronavirus Infections | 14 | 2020 | 253789 | 0.16 | Why? |
| Neprilysin | 1 | 2017 | 112 | 0.15 | Why? |
| Myocardium | 2 | 2017 | 2323 | 0.15 | Why? |
| Autonomic Nervous System | 1 | 2017 | 148 | 0.15 | Why? |
| Stroke Volume | 2 | 2018 | 2153 | 0.15 | Why? |
| Amyloidosis | 1 | 2017 | 178 | 0.14 | Why? |
| Salvage Therapy | 1 | 2017 | 417 | 0.14 | Why? |
| Cardiovascular Diseases | 4 | 2020 | 11497 | 0.13 | Why? |
| Hospital Mortality | 5 | 2021 | 22087 | 0.13 | Why? |
| Male | 28 | 2022 | 367725 | 0.13 | Why? |
| Radiography, Thoracic | 2 | 2021 | 5486 | 0.13 | Why? |
| Patient Admission | 2 | 2020 | 5250 | 0.13 | Why? |
| Tissue Inhibitor of Metalloproteinase-2 | 2 | 2019 | 45 | 0.12 | Why? |
| Electrocardiography | 4 | 2022 | 3957 | 0.12 | Why? |
| Betacoronavirus | 11 | 2020 | 204454 | 0.12 | Why? |
| Long QT Syndrome | 1 | 2022 | 1047 | 0.12 | Why? |
| Reproducibility of Results | 4 | 2021 | 11304 | 0.11 | Why? |
| Myocardial Contraction | 1 | 1992 | 123 | 0.11 | Why? |
| Antineoplastic Agents | 2 | 2017 | 3550 | 0.11 | Why? |
| Prognosis | 7 | 2020 | 32490 | 0.11 | Why? |
| Myocytes, Cardiac | 1 | 2017 | 804 | 0.11 | Why? |
| Cardiovascular System | 1 | 2019 | 750 | 0.11 | Why? |
| Humans | 40 | 2022 | 930598 | 0.11 | Why? |
| Regression Analysis | 2 | 2017 | 2484 | 0.11 | Why? |
| Aged | 19 | 2022 | 215776 | 0.11 | Why? |
| Middle Aged | 22 | 2022 | 270681 | 0.10 | Why? |
| Homes for the Aged | 1 | 2020 | 1071 | 0.10 | Why? |
| Heart Diseases | 2 | 2018 | 3503 | 0.10 | Why? |
| Female | 23 | 2022 | 380317 | 0.10 | Why? |
| Rats, Zucker | 2 | 2019 | 16 | 0.10 | Why? |
| Ventricular Function, Left | 2 | 2018 | 1555 | 0.10 | Why? |
| Rats | 3 | 2019 | 2764 | 0.10 | Why? |
| Heart Failure | 3 | 2021 | 6638 | 0.10 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 1454 | 0.09 | Why? |
| Antimalarials | 1 | 2021 | 2505 | 0.09 | Why? |
| Dexamethasone | 2 | 2017 | 2055 | 0.09 | Why? |
| Blood Pressure | 3 | 2005 | 2198 | 0.09 | Why? |
| Tertiary Care Centers | 3 | 2020 | 8248 | 0.09 | Why? |
| Hypertension | 3 | 2021 | 8895 | 0.09 | Why? |
| Sensitivity and Specificity | 2 | 2020 | 22971 | 0.09 | Why? |
| Hydroxychloroquine | 2 | 2022 | 12447 | 0.09 | Why? |
| Pandemics | 15 | 2021 | 389249 | 0.08 | Why? |
| Rats, Wistar | 2 | 2019 | 621 | 0.08 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.08 | Why? |
| Vitamin D Deficiency | 1 | 2020 | 1782 | 0.08 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.08 | Why? |
| Azithromycin | 1 | 2022 | 3943 | 0.08 | Why? |
| Diastole | 2 | 1999 | 168 | 0.08 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 5277 | 0.08 | Why? |
| Propranolol | 1 | 2005 | 36 | 0.08 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.08 | Why? |
| Smartphone | 1 | 2017 | 1840 | 0.07 | Why? |
| Renin-Angiotensin System | 2 | 2021 | 3661 | 0.07 | Why? |
| Cardiotoxicity | 2 | 2019 | 365 | 0.07 | Why? |
| Vitamin D | 1 | 2020 | 2904 | 0.07 | Why? |
| Dermatology | 1 | 2020 | 1999 | 0.07 | Why? |
| Poverty | 1 | 2017 | 2302 | 0.07 | Why? |
| Kidney | 1 | 2019 | 3648 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2021 | 3892 | 0.07 | Why? |
| Myocarditis | 1 | 2020 | 2731 | 0.07 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.07 | Why? |
| Collagen | 1 | 2005 | 222 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Skin Diseases | 1 | 2020 | 2509 | 0.07 | Why? |
| Intensive Care Units | 2 | 2020 | 29594 | 0.06 | Why? |
| Survival Rate | 4 | 2021 | 9206 | 0.06 | Why? |
| Nursing Homes | 1 | 2020 | 4155 | 0.06 | Why? |
| Biomarkers | 3 | 2020 | 23361 | 0.06 | Why? |
| Recurrence | 3 | 2017 | 3675 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.06 | Why? |
| Universities | 1 | 2018 | 4374 | 0.06 | Why? |
| Rats, Sprague-Dawley | 1 | 2005 | 987 | 0.06 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.06 | Why? |
| Adrenergic beta-Antagonists | 1 | 2005 | 465 | 0.06 | Why? |
| Fibrosis | 1 | 2005 | 800 | 0.06 | Why? |
| Obesity | 2 | 2020 | 7388 | 0.06 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.06 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.06 | Why? |
| Time Factors | 3 | 2020 | 31397 | 0.05 | Why? |
| Anatomic Landmarks | 1 | 2020 | 44 | 0.05 | Why? |
| Prospective Studies | 4 | 2020 | 43301 | 0.05 | Why? |
| Retrospective Studies | 7 | 2021 | 105322 | 0.05 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.05 | Why? |
| Thiobarbituric Acid Reactive Substances | 1 | 2019 | 20 | 0.05 | Why? |
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2019 | 33 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| Melphalan | 1 | 2017 | 46 | 0.04 | Why? |
| Adult | 13 | 2022 | 244371 | 0.04 | Why? |
| Analysis of Variance | 1 | 2021 | 950 | 0.04 | Why? |
| Amyloid | 1 | 2017 | 156 | 0.04 | Why? |
| Chi-Square Distribution | 1 | 2020 | 961 | 0.04 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.04 | Why? |
| Systole | 2 | 1999 | 252 | 0.04 | Why? |
| Minnesota | 1 | 2018 | 509 | 0.04 | Why? |
| Senegal | 1 | 2017 | 283 | 0.04 | Why? |
| Cytoplasm | 1 | 2017 | 304 | 0.04 | Why? |
| Primary Cell Culture | 1 | 2017 | 501 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.04 | Why? |
| Adolescent | 6 | 2021 | 86841 | 0.04 | Why? |
| Observer Variation | 1 | 2018 | 622 | 0.04 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.04 | Why? |
| Survival Analysis | 2 | 2020 | 7592 | 0.04 | Why? |
| Chemotherapy, Adjuvant | 1 | 2017 | 606 | 0.03 | Why? |
| Liver | 2 | 2019 | 4007 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2020 | 1262 | 0.03 | Why? |
| Drug Resistance, Neoplasm | 1 | 2017 | 447 | 0.03 | Why? |
| Risk Factors | 5 | 2022 | 71621 | 0.03 | Why? |
| Fibroblasts | 1 | 2017 | 839 | 0.03 | Why? |
| Animals | 5 | 2019 | 78931 | 0.03 | Why? |
| Cluster Analysis | 1 | 2021 | 3001 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2019 | 1136 | 0.03 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.03 | Why? |
| Manometry | 1 | 1992 | 91 | 0.03 | Why? |
| Ventricular Function | 1 | 1992 | 93 | 0.03 | Why? |
| Troponin I | 1 | 2020 | 1298 | 0.03 | Why? |
| Early Diagnosis | 1 | 2021 | 2443 | 0.03 | Why? |
| Hospitals, Teaching | 1 | 2020 | 1609 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.03 | Why? |
| Image Processing, Computer-Assisted | 1 | 2020 | 1383 | 0.03 | Why? |
| Disease Models, Animal | 2 | 2019 | 10998 | 0.03 | Why? |
| Ventricular Dysfunction, Left | 1 | 1999 | 993 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Mitochondria | 1 | 2017 | 857 | 0.03 | Why? |
| Phenotype | 1 | 2021 | 4037 | 0.02 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.02 | Why? |
| Antihypertensive Agents | 1 | 2021 | 1962 | 0.02 | Why? |
| Cardiomyopathies | 1 | 2017 | 997 | 0.02 | Why? |
| Heart | 1 | 2017 | 1791 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2020 | 51949 | 0.02 | Why? |
| Internationality | 1 | 2020 | 3297 | 0.02 | Why? |
| Chronic Disease | 1 | 2021 | 5139 | 0.02 | Why? |
| Arthritis, Rheumatoid | 1 | 1999 | 2043 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.02 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.02 | Why? |
| Telemedicine | 1 | 2017 | 25032 | 0.02 | Why? |
| Databases, Factual | 1 | 2020 | 6248 | 0.02 | Why? |
| Artificial Intelligence | 1 | 2020 | 3543 | 0.02 | Why? |
| Dogs | 1 | 1992 | 2529 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Magnetic Resonance Imaging | 1 | 2020 | 6551 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Europe | 1 | 2020 | 12702 | 0.02 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.02 | Why? |
| Treatment Outcome | 2 | 2021 | 51732 | 0.02 | Why? |
| Immunologic Factors | 1 | 2017 | 4206 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.01 | Why? |
| Mitral Valve | 1 | 1999 | 342 | 0.01 | Why? |
| Risk Assessment | 1 | 2019 | 25439 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Child | 1 | 2020 | 70012 | 0.01 | Why? |